Effect of Low-dose Esketamine Combined With Target-controlled Infusion of Propofol for Painless Gastrointestinal Endoscopy

Sponsor
Tianjin Union Medical Center (Other)
Overall Status
Recruiting
CT.gov ID
NCT04691076
Collaborator
(none)
1,000
1
2
14
71.3

Study Details

Study Description

Brief Summary

Purpose: 1. To determine the efficacy of low-dose esketamine in painless gastrointestinal endoscopy. 2. To determine the safety of low-dose esketamine in painless gastrointestinal endoscopy. 3. To provide a theoretical basis and new ideas for the application of esketamine as a new drug in perioperative period.

Condition or Disease Intervention/Treatment Phase
N/A

Detailed Description

Keeping spontaneous breathing anesthesia can provide patients with comfortable diagnosis and treatment experience during gastrointestinal endoscopy, which is a vital prerequisite for the large-scale development of this operation as well as the early screening and treatment of gastrointestinal malignancies. Clinically, fentanyl combined with propofol is the most commonly used anesthesia regimen for the painless gastroscopy, however its high incidence of respiratory and circulatory depression will threaten the safety of patients. Instead, esketamine has a good action in anesthesia and analgesics, a slighter respiratory depression, as well as with a remarkable improvement in adverse effects than ketamine. What has already been proved is that low- dose of esketamine can remarkably reduce the dosage of propofol during endoscopic retrograde cholangiopancreatography; In our pilot study, we found that not only the incidence of respiratory depression was significantly lower than that of fentanyl during endoscopic polypectomy, but also the dosage of propofol was reduced at the same time,suggesting that esketamine may have a potential superiority in the painless gastrointestinal endoscopy.Our project plans to collect the patients who have received painless gastroscopy and polypectomy in the hospital, and use a target-controlled infusion (TCI) of propofol in combination with esketamine, by observing the total dose of propofol , the time of recovery and the length of hospital stay, the satisfaction of patients and endoscopists, drug side effects,adverse events of respiratory and circulatory system and other indicators ,to evaluate the efficacy and safety of this anesthetic scheme.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
1000 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Efficacy and Safety of Low-dose Esketamine Combined With Target-controlled Infusion of Propofol for Painless Gastrointestinal Endoscopy and Polypectomy
Actual Study Start Date :
Dec 1, 2020
Anticipated Primary Completion Date :
Dec 1, 2021
Anticipated Study Completion Date :
Feb 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Propofol/Esketamine sedation

Propofol target-controlled infusion is performed first,when the infusion concentration reaches 1.5μg/ml,esketamine 0.15mg/kg is injected intravenously;then the dose is adjusted according to the depth of anesthesia and the modified observer's assessment of alert /sedation scale, and propofol target-controlled infusion for every increase of 5μg/ml in concentration, the corresponding increase of esketamine is 0.05mg/kg; the total dose of esketamine used in surgery shall not exceed 0.5mg/kg.

Drug: Propofol
Propofol is administered by target-controlled infusion

Drug: Esketamine
Esketamine is intravenously administrated

Active Comparator: Propofol/Fentanyl sedation

Propofol target-controlled infusion is performed first.When the infusion concentration reaches 1.5μg/ml, fentanyl 0.6μg/kg is injected intravenously; then the dose is adjusted according to the depth of anesthesia and the modified observer's assessment of alert /sedation scale, and propofol target-controlled infusion for every increase of 5μg/ml in concentration,the corresponding increase of fentanyl is 0.2ug/kg; the total dose of fentanyl used in surgery shall not exceed 1.2ug/kg.

Drug: Propofol
Propofol is administered by target-controlled infusion

Drug: Fentanyl
Fentanyl is intravenously administrated

Outcome Measures

Primary Outcome Measures

  1. Cumulative propofol Consumption [intraoperative]

    Total amount of propofol administered intraoperatively

Secondary Outcome Measures

  1. The incidence of adverse events in pulmonary and circulatory systems [During the operation]

    Pulmonary incidents include:Decreased blood oxygen saturation (SpO2 drops to 75%~90%, duration <60s);Severe decrease in blood oxygen saturation (SpO2<90%, duration>60s; or SpO2<75%);Obstruction of the airways occurs and requires the use of jaw manipulation or emergency airway equipment. Cardiovascular incidents include: Bradycardia or tachycardia; Arterial blood pressure increased or decreased by more than 20% of the baseline; Other matters requiring urgent attention.

  2. Time of recovery, post-anaesthesia care unit and discharge from hospital [procedure ( the end of endoscopy removal)]

    When the patient is successfully resuscitated,record the time in post-anaesthesia care unit and the time when the discharge standards are met.

  3. The incidence of side effects of esketamine [Intraoperative]

    Record the adverse effects of esketamine such as dizziness, nausea, etc.

  4. The number of patients'body movement during operation [During the operation]

    Record the patient's body movement during the operation, which reflects the level of sedation.

  5. The satisfaction of the endoscopist and patient [24 hours after surgery]

    Patients fill out questionnaires before and after surgery to record pain, sedation levels, and side effects (such as nausea and dizziness) to assess their satisfaction,meanwhile,telephone calls can be made one day after the surgery to evaluate their postoperative satisfaction.In addition, the satisfaction of the endoscopist with the sedation level could also recorded on a questionnaire after the operation.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 75 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  1. Subject's American Society of Anesthesiologists physical status is I-III.

  2. Subject has no symptoms of allergy to anesthetics.

  3. Subject has no contraindications for gastrointestinal endoscopy.

  4. Subject has given written informed consent to participate.

Exclusion Criteria:
  1. Subject's BMI <18 or >30

  2. Subject has poorly controlled or untreated hypertension.

  3. Subject has severe ischemic heart disease.

  4. Subject is an untreated or undertreated patient with hyperthyroidism.

  5. Subject has used drugs that affect their central nervous system.

  6. .Subject has mental illness.

  7. .Subject has epilepsy.

  8. .Subject has a history of chronic pain.

  9. .Subject is pregnant or breast-feeding.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Tianjin Union Medical Center Tianjin China 300131

Sponsors and Collaborators

  • Tianjin Union Medical Center

Investigators

  • Principal Investigator: Tao Yang, Tianjin Union Medical Center

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Tianjin Union Medical Center
ClinicalTrials.gov Identifier:
NCT04691076
Other Study ID Numbers:
  • TYang001
First Posted:
Dec 31, 2020
Last Update Posted:
Dec 31, 2020
Last Verified:
Dec 1, 2020
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Tianjin Union Medical Center
Additional relevant MeSH terms:

Study Results

No Results Posted as of Dec 31, 2020